Insulin and cancer: Report of the proceedings of the first international workshop

Pediatric Endocrinology Reviews

Volumn 5, Issue 3, 2008, Pages 810-816

  Renehan, Andrew G ^a   Berster, Jutta M ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cancer; Insulin; Insulin analogue; Insulin resistance; Insulin like growth factors

Indexed keywords

HEMOGLOBIN A1C; HUMANLOG; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN RECEPTOR; ISOPHANE INSULIN; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

CANCER EPIDEMIOLOGY; CONFERENCE PAPER; DIABETES MELLITUS; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; INTERNATIONAL COOPERATION; MALIGNANT NEOPLASTIC DISEASE; MITOGENESIS; SIDE EFFECT; WEIGHT GAIN;

CHILD; DIABETES MELLITUS, TYPE 1; EDUCATION; HUMANS; HYPERINSULINISM; INSULIN; NEOPLASMS; RISK FACTORS;

EID: 41549165167     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Werner H, Maor S. The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action. Trends Endocrinol Metab 2006;17(6):236-242
2. Shevah O, Laron Z. Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. Growth Horm IGF Res 2007;17(1):54-57
3. Frasca F, Pandini G, Vigneri R, Goldfine ID. Insulin and hybrid insulin/IGF receptors are major regulators of breast cancer cells. Breast Dis 2003;17:73-89
4. Frasca F, Pandini G, Malaguarnera R, Mandarino A, Messina RL, Sciacca L, Belfiore A, Vigneri R. Role of c-Abl in directing metabolic versus mitogenic effects in insulin receptor signaling. J Biol Chem 2007;282(36):26077-26088
5. WCRF. World Cancer Research Fund. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. 2nd ed. Washington: American Institute for Cancer Research; 2007
6. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006;17(8):328-336
7. Nagel JM, Goke B. (Colorectal carcinoma screening in patients with type 2 diabetes mellitus). Z Gastroenterol 2006;44(11):1153-1165
8. Waldhausl W. New insulin and insulin therapy: needs and reality. Exp Clin Endocrinol Diabetes 1999;107(Suppl 2):S44-S51
9. Hansen BF, Danielsen GM, Drejer K, Sorensen AR, Wiberg FC, Klein HH, Lundemose AG. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 1996;315( Pt 1):271-279
10. Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, Scionti L, Boli GB. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 2003;26(5):1490-1496
11. Eckardt K, May C, Koenen M, Eckel J. IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia 2007;50(12):2534-2543
12. Manara MC, Landuzzi L, Nanni P, Nicoletti G, Zambelli D, Lollini PL, Nanni C. Hofmann F, Garcia-Echeverria C, Picci P, Scotlandi K. Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma. Clin Cancer Res 2007;13(4):1322-1330
13. Chantelau E. Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol 1998;82(7):725-730
14. Paquot N, Philips JC, Radermecker R, Lefebvre P. (Recent advances in the management of diabetes mellitus). Rev Med Liege 2007;62(5-6):317-323
15. Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, Kaiser T. Pieber TR, Siebenhafer A. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007(2):CD005613
16. Le Roith D. Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes. Diabetes Metab Res Rev 2007;23(8):593-599
17. Zib I, Raskin P. Novel insulin analogues and its mitogenic potential. Diabetes Obes Metab 2006;8(6):611-620